Profiling of Peripheral TRBV and CD4+CD25+ Treg in CHB Patients with HBeAg SC during TDF Treatment

Figure 5

Prognostic value of the number of skewed TRBV families, Treg frequencies, and ALT levels in CHB subjects with or without HBeAg seroconverting (SC). The prognostic cutoff value of the number of skewed TRBV families at 48 weeks (a), Treg frequencies at 72 weeks (b), and ALT levels at baseline (c) in predicting the HBeAg SC of CHB subjects during TDF treatment for 96 weeks. The log-rank test was used to compare the difference of HBeAg SC among the CHB subjects during TDF treatment.

(a)

(b)

(c)